Trump Orders Fast-Track Psychedelic Research, Eyeing Ibogaine
Executive order directs $50 million to psychedelic research, adds three FDA priority-voucher spots and starts U.S. human-trial process for ibogaine.
CBS NewsTrump signs executive order to research psychedelics, including ibogaine, for mental health treatment
FOX NewsTrump-backed plan could fast-track psychedelic therapies — here’s what to know
Boston GlobeTrump signs order to speed review of psychedelics, like ibogaine
Western JournalTrump's Quick Reply to Joe Rogan's Text Message Brought Him to the White House: 'Do You Want FDA Approval?'
Overview
President Donald Trump on Saturday signed an executive order directing the administration to speed research and review of certain psychedelics, including ibogaine.
The order directs a $50 million federal research investment and will add three psychedelics to the FDAs National Priority Voucher pilot program, FDA commissioner Marty Makary said.
Health officials including Health and Human Services Secretary Robert F. Kennedy Jr., along with Joe Rogan and Marcus Luttrell, joined the president for the signing, and advocates hailed potential benefits for veterans.
A 2023 review of 24 studies covering 705 people reported at least 27 deaths linked to ibogaine, and clinic operator Tom Feegel said his clinic treated 2,000 people last year.
The FDA will begin steps to allow U.S. human trials of ibogaine and will issue national priority vouchers next week, while detailed federal implementation strategies remain under discussion.
Analysis
Center-leaning sources frame the action as a pragmatic response to a mental-health crisis, emphasizing research and supportive testimonials while offering limited skeptical context. They foreground presidential framing, federal funding, a JAMA study and veterans' trials, prioritize quotes from proponents (Rogan, Luttrell) and omit independent medical cautions or detailed safety analysis.